Global biotechnology company
focusing on developing new treatments

Sub Medpacto

Sub Medpacto

The national No.1 gene analysis company, to develop innovative biomarker-based therapeutics

MedPacto is an innovative drug discovery and development company based in South Korea that develops therapeutics targeting cancer and autoimmune diseases. Our expertise lies in utilizing genome-based methods to identify novel targets and function identification through pre-clinical studies and global clinical development.

There is urgent need for new treatments that can overcome the limitations of existing anticancer drugs and MedPacto develops pipelines according to the trends’ needs.

  • Founder

    Seong Jin Kim

  • Date of establishment

    19 Jun. 2013

  • Head Quarter

    92 Myeongdal-ro, Borim Building, Seocho-gu, Seoul 06668, Republic of Korea

IR BOOK DOWN

ESG

To contribute to the lives of patients and families by developing innovative and personalized therapies that target cancer and autoimmune diseases.

We continue to invest in R&D to develop innovative new drugs discovered through basic research, and we are promoting differentiated R&D through partnerships with leading research institutes at home and abroad.
In addition, we continue to make efforts to reduce energy use and greenhouse gas emissions in advance to cope with climate change. Moreover, as a listed company that must meet social expectations, Medpacto is practicing sustainability management to satisfy all stakeholders, including employees, customers, and shareholders.

MedPacto’s Corporate Culture

To discover and develop personalized therapies to meet the needs of patients by upholding ethical standards and scientific excellence.

  • Competitive basic research

  • ‘Biomarker-based’
    development of innovative drugs

  • Transparent and sincere company
    that puts customer trust first

  • Company whose
    employees are proud of

  • ‘One MedPacto’ mind

History

MedPacto : Our Roots

0000

Jun

2022. Jun.

Presented an online abstract of the clinical results of combination therapy for pancreatic cancer

  • Vactosertib + Polfox in pancreatic cancer

Feb

2022. Feb.

Business agreement for new drug development with Hits, an AI-based drug development company

Jan

2022. Jan.

Disclosed clinical design of combination therapy for pancreatic cancer at GI ASCO

Dec

2021. Dec.

Signed a phase 3 joint clinical contract with MSD for approval of Vactocertib + Keytruda in colon cancer

Nov

2021. Nov.

Disclosure of 2 biomarker research results at SITC

  • Vactosertib + Keytruda in colon cancer
  • Analysis of the relationship between the density and distribution of tissue infiltrating lymphocyte immune cells and the treatment prognosis

Aug

2021. Aug.

US FDA Designated as an orphan drug for Vactosertib monotherapy in osteosarcoma

Jul

2021. Jul.

US FDA Designated as an orphan drug for Vactosertib + onivyde combination therapy in pancreatic cancer

Jun

2021. Jun.

Presented colorectal cancer and multiple myeloma clinical data at ASCO

  • Vactosertib + Keytruda in colon cancer
  • Vactosertib + Pomalyst in multiple myeloma

Apr

2021. Apr.

Acquired patent for BAG2 target cancer antibody treatment

Apr

2021. Apr.

Abstracts published on 4 research results at AACR

  • Vactosertib + Onivyde in Pancreatic Cancer
  • TGF-β biomarker analysis result in desmoid tumor
  • Subsequent pipeline BAG2, DRAK1 R&D performance

Dec

2020. Dec.

Vactosertib, attracts 100 billion won investment for clinical trials for rare intractable diseases

Nov

2020. Nov.

Presented posters and abstracts related to Vactosertib at SITC

  • Vactosertib + Imfinzi in NSCLC
  • VRGS biomarker in colorectal cancer

Sep

2020. Sep.

US FDA designation as an orphan drug for Vactosertib + paclitaxel in gastric cancer

Sep

2020. Sep.

Vactosertib, European patent for blood cancer prevention and treatment substance

Sep

2020. Sep.

Presented the clinical data collaboration with paclitaxe at ESMO in gastric cancer

Aug

2020. Aug.

U.S. subsidiary Celloram attracts $7.5 million investment

May

2020. May.

Started clinical trial collaboration with MSD's Keytruda (pembrolizumab) in NSCLC

Dec

2019. Dec.

Enlisted on KOSDAQ stock market

Nov

2019. Nov.

Presented preliminary trial data at SITC 2019

  • Vactosertib + Keytruda in colon cancer
  • Vactosertib + Imfinzi in NSCLC

Jun

2019. Jun.

Secured $25M USD in Series C funding

Mar

2019. Mar.

Relocated MedPacto HQ to Seoul (Seocho district)

Dec

2018. Dec.

Presented preliminary trial data at ASH 2018

  • Vactosertib + Pomalyst in multiple myeloma

Dec

2018. Dec.

Started clinical trial collaboration with AstraZeneca's Imfinzi in bladder cancer

Jul

2018. Jul.

Started clinical trial collaboration with MSD's Keytruda for treatment of various solid tumors

Jul

2018. Jul.

Started clinical trial collaboration with AstraZeneca's Imfinzi (durvalumab) in NSCLC

Jun

2018. Jun.

Presented first-in-human phase 1 vactosertib clinical data at ASCO 2018

Apr

2018. Apr.

Secured $16M USD in Series A/B funding

Apr

2017. Apr.

Received US FDA IND approval for Phase 2 trials of Vactosertib

Sep

2016. Sep.

Relocated MedPacto HQ (Advanced Institute of Convergence Technology building)

Jul

2016. Jul.

Inaugurated Seong Jin Kim as new CEO

Apr

2014. Apr.

Received US FDA IND approval for Phase 1 study of Vactosertib

Dec

2013. Dec.

Obtained 'Certificate of Venture Company' from Korea Technology Finance Corporation (KIBO)

Jun

2013. Jun.

Established MedPacto, Inc (Gyeonggi R&D B Center)